Trial · NCT07278908
Avatrombopag Combined With All-trans Retinoic Acid in the Treatment of Primary Immune Thrombocytopenia
NCT07278908, Phase 2, Phase 3, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Avatrombopag Combined With All-trans Retinoic Acid in the Treatment of Primary Immune Thrombocytopenia. Trials, record NCT07278908. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07278908
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Avatrombopag Combined With All-trans Retinoic Acid in the Treatment of Primary Immune Thrombocytopenia
- NCT number
- NCT07278908
- Status
- Not yet recruiting
- Phases
- Phase 2, Phase 3
- Enrollment
- 248 participants, estimated
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Conditions
- ITP - Immune Thrombocytopenia
- Interventions
- Avatrombopag+All trans retinoic acid, Avatrombopag
- First posted
- 2025-12-12
- Last updated
- 2025-12-12
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Treatment Free Rate at week 52 | up to 52 weeks | |
| Secondary | At weeks 12 and 24 without rescue treatment, the proportion of subjects with platelet levels reaching CR, R, and ≥ 50 × 10^9/L, respectively | up to 12 and 24 weeks | |
| Secondary | Treatment Free Rate at week 12 after discontinuation of treatment | up to 12 weeks after discontinuation of treatment | |
| Secondary | The proportion of subjects whose platelet levels reached CR and R at 12 weeks after discontinuation of treatment | up to 12 weeks after discontinuation of treatment | |
| Secondary | The time from the start of treatment to the first platelet count ≥ 50 × 10^9/L | up to 52 weeks | From date of randomization until the date of first documented platelet count ≥ 50 × 10\^9/L, assessed up to 52 weeks |
| Secondary | The time required from the start of treatment to the first platelet count increasing by at least 2 times compared to the baseline platelet count | up to 52 weeks | From date of randomization until the date of first documented platelet count increasing by at least 2 times compared to the baseline platelet count, assessed up to 52 weeks |
| Secondary | The number of times subjects received rescue therapy during treatment and follow-up, and the proportion of subjects who received at least one rescue therapy | up to 52 weeks | |
| Secondary | World Health Organization(WHO) bleeding scoring criteria | up to 52 weeks | score range: 0-4; higher scores mean a worse outcome |
| Secondary | The Functional Assessment ot Chronic Illness Therapy-Fatigure(FACITF) score | up to 52 weeks | score range: 0-52; higher scores mean a worse outcome |
| Secondary | Adverse event | up to 52 weeks |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07278908
GET https://conductscience.org/api/trials/v1/NCT07278908/registered